NDAINJECTIONINJECTABLE
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIMARK (gadoversetamide) is a gadolinium-based contrast agent administered via injection for magnetic resonance imaging (MRI) enhancement. It is used to visualize and enhance tissue perfusion and vascular structures during MRI procedures. The drug works as a paramagnetic agent that alters local magnetic field properties to improve image contrast.
LOE Approaching
As LOE approaches, commercial teams face declining revenue and market share pressure; expect consolidation of field and marketing roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Started Feb 2009
0Nephrogenic Systemic FibrosisRenal Insufficiency
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Started May 2002
100 enrolled
Pathological Processes
Career Relevance
Working on OPTIMARK offers limited career growth opportunity given its LOE-approaching status and zero linked job postings. Roles focus on defending market share, managing pricing erosion, and transitioning to legacy product management as generics enter.
Product Manager
Worked on OPTIMARK at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.